Search the Newsreel

Valor Estate Q1FY26 loss widens to ₹4.53 crore despite flat revenue

ORVR3 - Orizon - Resultados, Dividendos, Cotação e Indicadores

Q3 EPS Estimate for AvalonBay Communities Boosted by Analyst

Zacks Research increased its Q3 2026 EPS estimate for AvalonBay Communities (NYSE:AVB) to $2.80, with a full-year forecast of $11.32 per share. The REIT's stock rose 2.4% to $184.12, despite recently missing consensus EPS estimates but exceeding revenue expectations. Institutional investors hold a significant …

DBREALTY: Q1 FY27 saw higher revenue but a net loss, with major acquisitions and legal matters pending

Sei Investments Co. Invests $849,000 in Avalo Therapeutics, Inc. $AVTX

Sei Investments Co. has acquired a new stake in Avalo Therapeutics (NASDAQ:AVTX), purchasing 56,854 shares valued at $849,000, which represents 0.19% of the company. Institutional investors now own 87.06% of AVTX, and analysts maintain a "Moderate Buy" rating with an average price target of …

Avalon Advanced Materials to Highlight Critical Minerals Strategy at Clean Energy Metals Investor Conference

AvalonBay, Equity Residential shareholders approve merger By Investing.com

Shareholders of AvalonBay Communities, Inc. (NYSE: AVB) and Equity Residential (NYSE: EQR) have overwhelmingly approved all proposals required to complete their merger of equals. The merger is anticipated to finalize on Monday, August 17, 2026, and the combined entity will be renamed Vivmark Residential, …

Handelsbanken Fonder AB Buys 32,137 Shares of AvalonBay Communities, Inc. $AVB

Handelsbanken Fonder AB increased its stake in AvalonBay Communities, Inc. (NYSE:AVB) by 41.1% during the second quarter, purchasing an additional 32,137 shares and bringing its total holdings to 110,350 shares valued at $20.82 million. Other institutional investors also adjusted their positions in the real …

Form 8K AvalonBay Communities Inc For: 12 August By Investing.com

This article reports the filing of a Form 8K by AvalonBay Communities Inc. for August 12, as reported by Investing.com. It briefly mentions the company and its stock performance. The article primarily consists of financial market data, news headlines, and navigational elements from the …

AvalonBay Communities (NYSE: AVB) holders approve merger and 2.793‑for‑1 share exchange

AvalonBay Communities stockholders overwhelmingly approved the proposed merger of equals with Equity Residential, along with merger-related compensation and an adjournment proposal, at a special meeting on August 12, 2026. The merger is expected to close on August 17, 2026, with each AvalonBay share converting …

Equity Residential, AvalonBay shareholders approve merger (EQR:NYSE)

Shareholders of AvalonBay Communities (AVB) and Equity Residential (EQR) have approved all proposals for their pending merger of equals. The announcement was made after separate special meetings held by each multifamily REIT.

Equity Residential and AvalonBay Communities Announce Shareholder Approvals for Merger to Create Vivmark Residential

Equity Residential and AvalonBay Communities announced that shareholders of both companies have overwhelmingly approved the merger to create Vivmark Residential. The merger is expected to close on Monday, August 17, 2026, and the combined company's shares will trade under the ticker symbol "VMRK" on …

Avalo Therapeutics (AVTX) CSO Riley sells 2,655 shares at about $19.59

Avalo Therapeutics' Chief Strategy Officer, Jennifer Riley, sold 2,655 shares of common stock on August 11, 2026, at a weighted average price of $19.5903 per share. The transactions occurred within a price range of $19.54 to $19.65. Following this sale, Riley directly holds 37,041 …

Avalo Therapeutics (AVTX) CMO Mittie Doyle exercises options and sells 679 shares

Avalo Therapeutics (AVTX) Chief Medical Officer Mittie Doyle exercised options for 679 shares at $8.04 per share and subsequently sold the same number of shares at $20.00 per share on August 10, 2026. These transactions were executed under a pre-established Rule 10b5-1 trading plan. …

Valor Gold Corp Stock Surges 4.77% as Trading Activity Spikes and Market Attention Builds

Why Valor Gold Corp. stock is rising today

Jefferies Adjusts Price Target on AvalonBay Communities to $201 From $205, Maintains Hold Rating

Jefferies has lowered its price target for AvalonBay Communities (AVB) to $201 from $205, while maintaining a Hold rating on the stock. This adjustment reflects an updated outlook from the analyst firm. AvalonBay Communities is a real estate investment trust specializing in apartment communities.

Avalo Therapeutics, Inc. $AVTX Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC significantly increased its stake in Avalo Therapeutics (NASDAQ:AVTX) by 556.4% in the first quarter, now owning 120,114 shares valued at $1.79 million. Despite this institutional interest, Avalo Therapeutics faces challenging financial prospects with missed earnings expectations and projected future losses. Wall …

Avalonbay Communities Inc. stock underperforms Tuesday when compared to competitors

Avalonbay Communities Inc. (AVB) stock fell 1.13% to $181.76 on Tuesday, underperforming the broader market. This marks the second consecutive day of losses for the company, as the S&P 500 and Dow Jones Industrial Average also experienced declines.

Avalon Advanced Materials to Court Investors at UBS Global Materials Conference

Equities Analysts Issue Forecasts for AVTX Q3 Earnings

AvalonBay Communities, Inc. $AVB Shares Sold by PensionDanmark Pensionsforsikringsaktieselskab

PensionDanmark Pensionsforsikringsaktieselskab significantly reduced its stake in AvalonBay Communities (NYSE: AVB) by 84% in the second quarter, selling 21,622 shares and retaining 4,120 shares valued at approximately $777,000. Despite the sell-off, institutional investors still collectively own 92.61% of AVB. Wall Street analysts generally hold …

Do Avalo Therapeutics’ (AVTX) Widening Losses But Better EPS Reveal a Turning Point in Strategy?

AvalonBay Communities (AVB) Faces A Valuation Test, Is An 9% Discount Enough?

AvalonBay Communities (AVB) has experienced recent stock price declines but is considered 8.7% undervalued with a fair value of $201.44 per share, according to Simply Wall St. The valuation is supported by expected long-term undersupply of housing and strong demand in its key markets, …

What's Going On With Avalon Advanced Materials Ltd Stock Monday?

Bank of America Securities Reaffirms Their Buy Rating on Avalo Therapeutics (AVTX)

Bank of America Securities analyst Alec Stranahan reaffirmed a Buy rating on Avalo Therapeutics (AVTX) with a price target of $35.00. This comes despite the company reporting a wider GAAP net loss of $36.36 million in its latest quarterly earnings compared to the previous …

Aurora Investment Managers LLC. Reduces Position in AvalonBay Communities, Inc. $AVB

Aurora Investment Managers LLC significantly reduced its stake in AvalonBay Communities (AVB) by 85.2% in the second quarter, selling 14,579 shares and retaining 2,528 shares valued at $477,000. Despite this, other institutional investors increased their holdings, and institutions collectively own 92.61% of AVB. AvalonBay …

Avalo Therapeutics (NASDAQ:AVTX) Rating Lowered to "Sell" at Wall Street Zen

Quantinno Capital Management LP Sells 23,317 Shares of AvalonBay Communities, Inc. $AVB

Quantinno Capital Management LP significantly reduced its stake in AvalonBay Communities, Inc. ($AVB) by selling 23,317 shares, a 40.4% cut, leaving them with 34,396 shares valued at $5.6 million. Despite institutional ownership of 92.61%, Wall Street analysts largely maintain a "Hold" rating for the …

Avalon Holdings (NYSE: AWX) returns to Q2 profit, details debt and cash

Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $45.80, significantly above its current trading price of $18.70. Despite strong institutional ownership at 87.06% and recent buying activity, the company reported an adjusted …

AVTX Maintains Buy Rating by Guggenheim -- Price Target Lowered to $48

Guggenheim maintained a Buy rating for Avalo Therapeutics (AVTX) but lowered its price target from $50.00 to $48.00, reflecting a cautious outlook due to clinical development challenges. The stock is considered significantly overvalued with a GF Value™ of $0.03 against a current price of …

Avalo Therapeutics Inc (AVTX) Earnings Forecast: Future EPS & Revenue Growth Estimates